The FDA shortage designations that let compounding pharmacies mass-produce copies of semaglutide and tirzepatide have c ...

With an estimated 2 million people in the United States taking copycat versions of Eli Lilly and Novo Nordisk’s incretin hormone drugs, compounding pharmacies have suddenly thrived from their ability ...

Tirzepatide is a dual GLP-1 and GIP receptor agonist that mimics two hormones in the gut that help regulate blood sugar, reduce hunger cues and slow digestion. It’s the active ingredient in the ...

The FDA's proposal could reshape access to compounded GLP-1 drugs, affecting costs, supply, and patient options.

In a reversal, the Food and Drug Administration (FDA) said it will allow some compounding pharmacies to temporarily make their own versions of tirzepatide, the active ingredient in Eli Lilly’s ...

Four days after a compounding industry group filed a lawsuit against the FDA for removing Eli Lilly’s tirzepatide products from its shortage list, the U.S. regulator is taking a second look at its ...

Pharmacists may continue making compounded versions of the weight-loss medication tirzepatide while the U.S. Food and Drug Administration revisits its Oct. 2 decision to remove the medicine from a ...

(RTTNews) - Eli Lilly And Co. (LLY) filed lawsuits Tuesday against Strive Pharmacy and Empower Pharmacy, accusing them of unlawfully compounding and selling tirzepatide, the active ingredient in its ...

Individuals with commercial insurance can use manufacturer savings cards to bring the price down to as low as $25 for a one- ...

On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved” for ...

Glucagon-like peptide-1 agonists, a class of medications known as GLP-1s, have grown in popularity, initially for the treatment of type 2 diabetes and more recently for obesity and other labeled and ...